ISEMBYLD
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- ISEMBYLD
- Generic name
- APITEGROMAB-MSTN
- Manufacturer
- Scholar Rock, Inc.
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- b1cd8ab8-8a10-48ed-9806-75a44f22b963
- SPL ID
- 5554cf70-b144-11f1-ab3b-0800200c9a66
- Version
- 3
- Effective date
- 2026-09-14
- Source export date
- 2026-11-13
- Source partition
- 10
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0010-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/829e43b83940afb8dda22d5287c5b17e57d3fe45d1157678854b4f9b7ad07271/drug-label-0010-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 17:15:28
| Harmonized routes |
|---|
| INTRAVENOUS |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | BLA | 761463 | derived:openfda.application_number |
| application number | BLA761463 | openfda.application_number | |
| brand name | ISEMBYLD | openfda.brand_name | |
| generic name | APITEGROMAB-MSTN | openfda.generic_name | |
| manufacturer name | Scholar Rock, Inc. | openfda.manufacturer_name | |
| ndc | package | 84717-150-01 | openfda.package_ndc |
| ndc | product | 84717-150 | openfda.product_ndc |
| ndc11 | package | 84717015001 | derived:openfda.package_ndc |
| rxcui | 2753169 | openfda.rxcui | |
| rxcui | 2753176 | openfda.rxcui | |
| spl id | 5554cf70-b144-11f1-ab3b-0800200c9a66 | id | |
| spl set id | b1cd8ab8-8a10-48ed-9806-75a44f22b963 | set_id | |
| unii | UZ54216N0Y | openfda.unii |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
5 WARNINGS AND PRECAUTIONS Fractures: Serious fracture events have occurred in patients treated with ISEMBYLD. Use with caution in patients with a history of low bone density or multiple fractures. In patients who experience fractures, weigh the risks and benefits of continuing ISEMBYLD. ( 5.1 ) 5.1 Fractures ISEMBYLD may increase the risk of fractures, including serious fractures [see Adverse Reactions ( 6.1 )] . In Study 1 [see Clinical Studies ( 14 )] , 5/53 (9%) of patients treated with ISEMBYLD 10 mg/kg and 3/53 (6%) of patients treated with ISEMBYLD 20 mg/kg (twice the recommended dosage) experienced fractures compared with one patient in the placebo group (2%) who had a fracture. Femur fractures occurred in three patients treated with ISEMBYLD in Study 1. No patients discontinued treatment due to fractures. In an ongoing open label extension study in which patients received ISEMBYLD 20 mg/kg (twice the recommended dosage), fractures occurred in 22 patients (9%), including 5 serious events of femur fractures. Most patients with fractures had histories of low bone density or previous fractures, or contractures. Some fracture events did not have a clear precipitating event (such as a fall). Animal studies have also demonstrated adverse effects in bone [see Nonclinical Toxicology ( 13.2 )] . Use ISEMBYLD with caution in patients with a history of low bone density or multiple fractures. In patients who experience fractures, weigh the risks and benefits of continuing ISEMBYLD.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: Fractures [see Warnings and Precautions ( 5.1 )] Most common adverse reactions in SMA (incidence greater than or equal to 20% of patients treated with ISEMBYLD and more frequent than placebo) were upper respiratory tract infections, vomiting, cough, other viral infections, headache, gastroenteritis, pharyngitis, and hypersensitivity.( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Scholar Rock, Inc. at 1-855-MED-SRRK (1-855-633-7775) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety of ISEMBYLD for SMA was evaluated in a randomized, double-blind, and placebo-controlled study (Study 1) [see see Clinical Studies ( 14 )] . In Study 1, ISEMBYLD was evaluated in 128 patients with SMA (2 to 21 years at the start of the study), which included 53 patients 2 to 12 years of age [mean 7 years of age] who received the recommended dosage of ISEMBYLD (10 mg/kg once every 4 weeks) for a mean exposure of 49 weeks. Of those 53 patients, 43% were female, 66% were White, 11% were of Hispanic or Latino ethnicity, 4% were Asian, and 2% were Black or African-American. The adverse reaction information presented below is from the patients who received the recommended dosage of ISEMBYLD, unless otherwise noted. The most common adverse reactions (reported in at least 20% of patients treated with ISEMBYLD and more frequently than in placebo) were upper respiratory tract infections, vomiting, cough, other viral infections, headache, gastroenteritis, pharyngitis, and hypersensitivity. Table 1 lists the common adverse reactions that occurred in at least 5% of patients treated with ISEMBYLD and at least 5% more frequently than placebo. Table 1: Adverse Reactions Reported in ≥ 5% of Patients with SMA Treated with ISEMBYLD 10 mg/kg and ≥ 5% More Frequently than in Placebo (Study 1) 1 Includes nasopharyngitis, rhinovirus infection, sinusitis, viral upper respiratory tract infection, upper respiratory tract infection, nasal congestion, rhinorrhea, rhinitis. 2 Includes metapneumovirus infection, parvovirus B19 infection, COVID-19, respiratory syncytial virus infection, respiratory syncytial virus bronchiolitis, influenza, parainfluenzae, adenovirus, respiratory tract infection viral, and viral infection. 3 Includes other similar terms. 4 Includes pharyngitis, pharyngitis streptococcal, oropharyngeal pain. 5 Includes dermatitis acneiform, dermatitis atopic, eczema, flushing, rash, rash maculo-papular, urticaria. 6 Includes application site reaction, catheter site pain, infusion related reaction, infusion site bruising, infusion site pain, injection site bruising, injection site pain. 7 Includes other similar terms 8 Includes foot fracture, clavicle fracture, femur fracture, tibia fracture, torus fracture. 9 Includes fatigue, lethargy. Adverse Reaction ISEMBYLD (10 mg/kg) (N = 53) % Placebo (N = 50) % Upper respiratory tract infections 1 66 54 Vomiting 30 16 Cough 28 22 Other viral infections 2 26 16 Headache 23 16 Gastroenteritis 3 23 8 Pharyngitis 4 21 14 Hypersensitivity 5 21 16 Diarrhea 17 0 Injection site reactions 6 13 0 Abdominal pain 7 13 6 Arthralgia 13 4 Contusion 11 6 Fall 11 6 Fractures 8 9 2 Fatigue 9 9 2 Pain in extremity 9 4 Hematoma 6 0 Myalgia 6 0 Acute Respiratory Failure In Study 1, serious events of acute respiratory failure in the setting of lower respiratory tract infections occurred in two patients treated with ISEMBYLD at a dose of 10 mg/kg and in one patient that received placebo. Pneumonia In Study 1, serious adverse events of pneumonia occurred in three patients treated with ISEMBYLD at a dose of 10 mg/kg and in no patients that received placebo. Laboratory Findings Creatine Phosphokinase In Study 1, CPK increases were seen more frequently in patients treated with ISEMBYLD 10 mg/kg (n=53) compared to placebo (n=50). By month 12, mean CPK levels increased by 91 U/L in patients treated with ISEMBYLD compared to 3 U/L in placebo. Increases in CPK were seen in 28% of patients treated with ISEMBYLD, compared to 12% in placebo; among these, 3 patients (6%) treated with ISEMBYLD had CPK elevations of greater than 2.5 times the upper limit of normal (ULN), compared to none in placebo. Similar patterns of elevations were seen in patients receiving ISEMBYLD who were over 12 years of age compared to those 2 to 12 years of age. One patient with elevated CPK at baseline who received ISEMBYLD 20 mg/kg (twice the recommended dosage) in the 13 to 21 age group had further CPK increases to greater than 10 times the ULN. Patients with CPK elevations in Study 1 have generally been asymptomatic.
adverse reactions table
<table ID="table1" width="700" styleCode="Noautorules"> <caption>Table 1: Adverse Reactions Reported in ≥ 5% of Patients with SMA Treated with ISEMBYLD 10 mg/kg and ≥ 5% More Frequently than in Placebo (Study 1)</caption> <col width="38%" align="left" valign="top"/> <col width="32%" align="center" valign="top"/> <col width="32%" align="center" valign="top"/> <tfoot> <tr> <td colspan="3"> <sup>1</sup> Includes nasopharyngitis, rhinovirus infection, sinusitis, viral upper respiratory tract infection, upper respiratory tract infection, nasal congestion, rhinorrhea, rhinitis. <sup>2</sup> Includes metapneumovirus infection, parvovirus B19 infection, COVID-19, respiratory syncytial virus infection, respiratory syncytial virus bronchiolitis, influenza, parainfluenzae, adenovirus, respiratory tract infection viral, and viral infection. <sup>3</sup> Includes other similar terms. <sup>4</sup> Includes pharyngitis, pharyngitis streptococcal, oropharyngeal pain. <sup>5</sup> Includes dermatitis acneiform, dermatitis atopic, eczema, flushing, rash, rash maculo-papular, urticaria. <sup>6</sup> Includes application site reaction, catheter site pain, infusion related reaction, infusion site bruising, infusion site pain, injection site bruising, injection site pain. <sup>7</sup> Includes other similar terms <sup>8</sup> Includes foot fracture, clavicle fracture, femur fracture, tibia fracture, torus fracture. <sup>9</sup> Includes fatigue, lethargy.</td> </tr> </tfoot> <tbody> <tr> <td styleCode="Toprule Botrule Lrule Rrule bold">Adverse Reaction</td> <td styleCode="Toprule Botrule Lrule Rrule bold">ISEMBYLD (10 mg/kg) (N = 53) %</td> <td styleCode="Toprule Botrule Lrule Rrule bold">Placebo (N = 50) %</td> </tr> <tr> <td styleCode="Toprule Botrule Lrule Rrule">Upper respiratory tract infections<sup>1</sup> </td> <td styleCode="Toprule Botrule Lrule Rrule">66</td> <td styleCode="Toprule Botrule Lrule Rrule">54</td> </tr> <tr> <td styleCode="Toprule Botrule Lrule Rrule">Vomiting</td> <td styleCode="Toprule Botrule Lrule Rrule">30</td> <td styleCode="Toprule Botrule Lrule Rrule">16</td> </tr> <tr> <td styleCode="Toprule Botrule Lrule Rrule">Cough</td> <td styleCode="Toprule Botrule Lrule Rrule">28</td> <td styleCode="Toprule Botrule Lrule Rrule">22</td> </tr> <tr> <td styleCode="Toprule Botrule Lrule Rrule">Other viral infections<sup>2</sup> </td> <td styleCode="Toprule Botrule Lrule Rrule">26</td> <td styleCode="Toprule Botrule Lrule Rrule">16</td> </tr> <tr> <td styleCode="Toprule Botrule Lrule Rrule">Headache</td> <td styleCode="Toprule Botrule Lrule Rrule">23</td> <td styleCode="Toprule Botrule Lrule Rrule">16</td> </tr> <tr> <td styleCode="Toprule Botrule Lrule Rrule">Gastroenteritis<sup>3</sup> </td> <td styleCode="Toprule Botrule Lrule Rrule">23</td> <td styleCode="Toprule Botrule Lrule Rrule">8</td> </tr> <tr> <td styleCode="Toprule Botrule Lrule Rrule">Pharyngitis<sup>4</sup> </td> <td styleCode="Toprule Botrule Lrule Rrule">21</td> <td styleCode="Toprule Botrule Lrule Rrule">14</td> </tr> <tr> <td styleCode="Toprule Botrule Lrule Rrule">Hypersensitivity<sup>5</sup> </td> <td styleCode="Toprule Botrule Lrule Rrule">21</td> <td styleCode="Toprule Botrule Lrule Rrule">16</td> </tr> <tr> <td styleCode="Toprule Botrule Lrule Rrule">Diarrhea</td> <td styleCode="Toprule Botrule Lrule Rrule">17</td> <td styleCode="Toprule Botrule Lrule Rrule">0</td> </tr> <tr> <td styleCode="Toprule Botrule Lrule Rrule">Injection site reactions<sup>6</sup> </td> <td styleCode="Toprule Botrule Lrule Rrule">13</td> <td styleCode="Toprule Botrule Lrule Rrule">0</td> </tr> <tr> <td styleCode="Toprule Botrule Lrule Rrule">Abdominal pain<sup>7</sup> </td> <td styleCode="Toprule Botrule Lrule Rrule">13</td> <td styleCode="Toprule Botrule Lrule Rrule">6</td> </tr> <tr> <td styleCode="Toprule Botrule Lrule Rrule">Arthralgia</td> <td styleCode="Toprule Botrule Lrule Rrule">13</td> <td styleCode="Toprule Botrule Lrule Rrule">4</td> </tr> <tr> <td styleCode="Toprule Botrule Lrule Rrule">Contusion</td> <td styleCode="Toprule Botrule Lrule Rrule">11</td> <td styleCode="Toprule Botrule Lrule Rrule">6</td> </tr> <tr> <td styleCode="Toprule Botrule Lrule Rrule">Fall</td> <td styleCode="Toprule Botrule Lrule Rrule">11</td> <td styleCode="Toprule Botrule Lrule Rrule">6</td> </tr> <tr> <td styleCode="Toprule Botrule Lrule Rrule">Fractures<sup>8</sup> </td> <td styleCode="Toprule Botrule Lrule Rrule">9</td> <td styleCode="Toprule Botrule Lrule Rrule">2</td> </tr> <tr> <td styleCode="Toprule Botrule Lrule Rrule">Fatigue<sup>9</sup> </td> <td styleCode="Toprule Botrule Lrule Rrule">9</td> <td styleCode="Toprule Botrule Lrule Rrule">2</td> </tr> <tr> <td styleCode="Toprule Botrule Lrule Rrule">Pain in extremity</td> <td styleCode="Toprule Botrule Lrule Rrule">9</td> <td styleCode="Toprule Botrule Lrule Rrule">4</td> </tr> <tr> <td styleCode="Toprule Botrule Lrule Rrule">Hematoma</td> <td styleCode="Toprule Botrule Lrule Rrule">6</td> <td styleCode="Toprule Botrule Lrule Rrule">0</td> </tr> <tr> <td styleCode="Toprule Botrule Lrule Rrule">Myalgia</td> <td styleCode="Toprule Botrule Lrule Rrule">6</td> <td styleCode="Toprule Botrule Lrule Rrule">0</td> </tr> </tbody> </table>
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.